Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $6.32 up 1.44% from its previous closing price of $6.23. In other words, the price has increased by $1.44 from its previous closing price. On the day, 1.8 million shares were traded. AQST stock price reached its highest trading level at $6.435 during the session, while it also had its lowest trading level at $6.17.
Ratios:
For a deeper understanding of Aquestive Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.62 and its Current Ratio is at 5.93.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $17. On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.Leerink Partners initiated its Outperform rating on May 10, 2024, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 17 ’25 when Carl N. Kraus bought 53,100 shares for $5.39 per share.
Jung Cassie sold 67,575 shares of AQST for $473,701 on Oct 15 ’25. The Chief Operating Officer now owns 240,771 shares after completing the transaction at $7.01 per share. On Oct 15 ’25, another insider, Kraus Carl N, who serves as the Chief Medical Officer of the company, sold 20,272 shares for $7.00 each. As a result, the insider received 141,904 and left with 282,475 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 771059712 and an Enterprise Value of 683372672. For the stock, the TTM Price-to-Sale (P/S) ratio is 17.77. Its current Enterprise Value per Revenue stands at 15.747 whereas that against EBITDA is -12.379.
Stock Price History:
The Beta on a monthly basis for AQST is 1.66, which has changed by 0.7506925 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, AQST has reached a high of $7.55, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is 0.43%, while the 200-Day Moving Average is calculated to be 50.24%.
Shares Statistics:
For the past three months, AQST has traded an average of 3.18M shares per day and 2183750 over the past ten days. A total of 121.66M shares are outstanding, with a floating share count of 114.17M. Insiders hold about 6.42% of the company’s shares, while institutions hold 51.22% stake in the company. Shares short for AQST as of 1764288000 were 19825552 with a Short Ratio of 6.24, compared to 1761868800 on 14739130. Therefore, it implies a Short% of Shares Outstanding of 19825552 and a Short% of Float of 18.63.
Earnings Estimates
. The current rating of Aquestive Therapeutics Inc (AQST) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.13 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.57 and -$0.58 for the fiscal current year, implying an average EPS of -$0.57. EPS for the following year is -$0.45, with 3.0 analysts recommending between -$0.44 and -$0.45.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $13.35M this quarter.It ranges from a high estimate of $14.3M to a low estimate of $11.4M. As of. The current estimate, Aquestive Therapeutics Inc’s year-ago sales were $11.87MFor the next quarter, 10 analysts are estimating revenue of $11.52M. There is a high estimate of $14.4M for the next quarter, whereas the lowest estimate is $9.5M.
A total of 10 analysts have provided revenue estimates for AQST’s current fiscal year. The highest revenue estimate was $45.8M, while the lowest revenue estimate was $42.9M, resulting in an average revenue estimate of $44.87M. In the same quarter a year ago, actual revenue was $57.56MBased on 10 analysts’ estimates, the company’s revenue will be $68.46M in the next fiscal year. The high estimate is $83.62M and the low estimate is $51.5M.
